Highest-materiality recent filing
GridAI Technologies raises $8.5M in private placement of common stock and warrants
Sold 108,932 shares, pre-funded warrants for 1,742,991 shares, and common warrants for 1,851,923 shares at $4.59 per unit.
GridAI raises ~$8.5M in private placement of common stock and warrants
Gross proceeds of ~$8.5M from sale of 664,598 shares, 1,187,325 pre-funded warrants, and 1,851,923 common warrants.
GridAI settles $1.03M debt with $800K cash and 71,482 common shares at $3.25/share
Settlement resolves $1,032,315 owed under Revolving Loan Agreement; avoids default demand.
GridAI Technologies Corp. raises ~$7.8M in private placement of common stock and warrants
Gross proceeds of ~$2.54M: 74,000 shares, 1,196,001 pre-funded warrants at $0.00001, and 1,270,001 common warrants at $2.00/unit.
GridAI regains Nasdaq compliance after filing delinquent 2025 10-K
Filed its 2025 Form 10-K on May 1, 2026, which was past the original due date.
GridAI receives Nasdaq notice for late 10-K filing; 60-day compliance plan deadline
Received Nasdaq deficiency letter on April 22, 2026 for failing to file FY2025 10-K by deadline.
GridAI receives loan default demand for $1.01M from lender
Demand letter received April 1, 2026, asserts default on $700,000 principal under Revolving Loan Agreement.
GridAI Technologies provides acquired GridAI audited financials: $3.3M net loss, going concern
GridAI net loss of $5.3M for inception-to-Sept 2025; $3.3M loss attributable to GridAI on $139K revenue.
GridAI completes rescission of ImmunogenX acquisition, removes $83.2M in assets
Rescission completed Dec 31, 2025; Immuno LLC is no longer a subsidiary.
Jason D. Sawyer appointed permanent CEO effective Dec 19, 2025, transitioning from interim role.
GridAI director Corbett resigns citing governance concerns; ticker changes to GRDX
Director Eric Corbett resigned due to disagreements over financial statement accuracy, GRID AI due diligence, and press release quality.
GridAI stockholders waive board appointment rights pending shareholder approval
GridAI stockholders waived right to appoint two directors to Entero board until shareholder vote.
Nasdaq confirms Entero Therapeutics regains compliance with equity rule
Nasdaq letter dated Oct 28, 2025 confirms company meets $2.5M minimum stockholders' equity requirement.
Entero Therapeutics enters up to $5M securities purchase agreement with initial $500k closing
Initial closing of $500k non-interest bearing promissory note due one year and one day from issuance.
Acquired 100% of GridAI for 424,348 common shares (19.99% of outstanding) and 38,801,546 Series H convertible shares.
Jason D. Sawyer appointed Interim CEO via consulting agreement with Access Alternative Group S.A., effective Sept 4, 2025.
Entero Therapeutics replaces Interim CEO; appoints Jason D. Sawyer
Richard Joel Paolone terminated as Interim CEO and Chairman, effective Sept 3, 2025, without cause.
Entero Therapeutics announces 1-for-3 reverse stock split to regain Nasdaq compliance
Reverse stock split at ratio 1-for-3 effective 12:01 a.m. ET on August 18, 2025.
Entero Therapeutics raises $3M in private placement; appoints two new directors
Gross proceeds of $3.0M from sale of pre-funded warrants and common warrants priced at $0.6149 per unit.
Amendment adds Section 5(f) to Rescission Agreement, requiring each shareholder to be an accredited investor under Rule 501 of Regulation D.
Entero Therapeutics regains Nasdaq annual meeting compliance
Received Nasdaq letter confirming compliance with Listing Rule 5620(a) after holding Annual Meeting on June 30, 2025.
Entero Therapeutics shareholders approve reverse stock split authorization at annual meeting
Stockholders authorized a reverse stock split at ratio between 1:2 and 1:20, with board discretion to set ratio within one year.
Nasdaq grants Entero Therapeutics extension to Oct 8, 2025 to meet minimum equity requirement
Company received Nasdaq extension letter on June 25, 2025; deadline to regain compliance is October 8, 2025.
ImmunogenX subsidiary settled lawsuit with Mattress Liquidators; guarantors paid $5.5M of ~$7.9M owed on Apr 9, 2025.
Entero Therapeutics receives Nasdaq deficiency notice for stockholders' equity shortfall
Stockholders' equity of ($3,876,738) as of Dec 31, 2024, well below Nasdaq's $2.5M minimum.
Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO
Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.
Nasdaq extends Entero bid price compliance to Sept 1, 2025; CFO resigns, Skowron named CFO
Nasdaq granted extension until Sept 1, 2025 to regain $1.00 minimum bid price compliance.
Entero Therapeutics terminates CEO James Sapirstein, appoints Richard Paolone as interim CEO
James Sapirstein terminated as CEO without cause effective February 12, 2025.
Entero Therapeutics enters $2M loan at 18%; lender gains board control, replaces three directors
Revolving loan up to $2M from 1396974 BC Ltd.; initial $550K drawn Jan 31, 2025 at 18% interest, due Jan 31, 2026.
Entero Therapeutics receives Nasdaq notice for missing 2024 annual meeting
Notice received Jan 7, 2025 for non-compliance with Nasdaq Listing Rule 5620(a) due to no 2024 annual meeting.
Entero Therapeutics subsidiary receives default notice; $7.4M debt accelerated
ImmunogenX received default notice on Nov 21, 2024 from lender Mattress Liquidators, Inc., accelerating ~$7.4M in obligations.
Entero Therapeutics to reverse-merge with Journey Therapeutics, issuing 99% equity
Entero (ENTO) signs binding term sheet to acquire all Journey equity; Journey holders get 99% of combined company.
Entero Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq notified Entero on Sept 6, 2024 that common stock failed minimum $1.00 bid price for 30 consecutive business days.
Entero Therapeutics signs LOI to license clinical trial compliance platform from DataVault Holdings
Binding LOI for exclusive worldwide license to QOLPOM and FotoDigm clinical trial software from DataVault Holdings.
Entero Therapeutics subsidiary receives default suspension, but no waiver
On August 29, 2024, ImmunogenX received letter from Lender Mattress Liquidators suspending MAE Default under Credit Agreement.
Entero Therapeutics appoints Machias Gini & O'Connell LLP as new auditor
Appointed MGO as independent registered public accounting firm effective August 27, 2024, subject to stockholder ratification.
Entero Therapeutics receives Nasdaq non-compliance notice for late Form 10-Q filing
Nasdaq notice on Aug 21, 2024, for failure to timely file Q2 2024 Form 10-Q.
Chaitan Khosla resigned from Board effective August 16, 2024.
Entero Therapeutics' auditor Forvis Mazars resigns over financial reporting reliability concerns
Forvis Mazars resigned as independent auditor on Aug 9, 2024, citing belief that cost reduction measures prevent reliable financial reporting.
Entero Therapeutics faces $7M debt acceleration, board resignations, workforce cuts, R&D pause
ImmunogenX subsidiary received default notice accelerating $6,997,583 in obligations under Credit Agreement.
Entero Therapeutics provides latiglutenase Phase 3 plan, FDA meetings, $1.9M raise
Submits Type D requests to FDA to streamline Phase 3 trial cohorts from three to two (1200 mg and placebo).
Entero Therapeutics CSO Jack Syage resigns; salary cut to $66,560 as cost reduction
Dr. Jack Syage resigned as Chief Scientific Officer effective July 17, 2024, will remain President and Board member.
Gross proceeds of ~$1.9M from cash exercise of 1,762,674 existing warrants at a reduced price of $1.09 per share.
Entero Therapeutics transitions COO Jack Syage to Chief Scientific Officer
Jack Syage, previously President and COO, appointed Chief Scientific Officer effective June 17, 2024.
Entero Therapeutics replaces auditor Mazars with Forvis Mazars effective June 1, 2024
Mazars USA LLP resigned after its partners and employees joined FORVIS LLP; the combined firm is now Forvis Mazars LLP.
Entero Therapeutics files Q1 2024 pro forma statements post-ImmunogenX merger
Amendment adds unaudited pro forma combined statement of operations for three months ended March 31, 2024.
First Wave BioPharma changes name to Entero Therapeutics; ticker to ENTO effective May 17
Name change from First Wave BioPharma to Entero Therapeutics effective May 17, 2024.
First Wave BioPharma raises ~$1.1M in registered direct offering priced at $2.95/share
Gross proceeds expected ~$1.1M; net proceeds ~$0.9M after agent fees.
ImmunogenX reports net loss of $8.86M in 2023; auditor cites going concern doubts
Net loss for 2023 was $8.86M, compared to $3.62M in 2022 and $1.66M in 2021.
Nasdaq issues reprimand to First Wave BioPharma for shareholder approval lapse; matter closed
On March 19, 2024, Nasdaq issued a Letter of Reprimand for the July 2023 offering of 610k shares and warrants at $0.64/share.
On March 3, 2025, Ms. Sarah Romano informed the Company of her resignation as Chief Financial Officer of the Company, effective as of March 7, 2025.
on March 3, 2025, the Company appointed Ms. Anna Skowron as Chief Financial Officer of the Company, effective as of March 7, 2025
On February 12, 2025, Richard Joel Paolone was appointed to serve as Interim Chief Executive Officer of the Company and Chairman of the Board, effective immediately.
On February 12, 2025, the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”) terminated James Sapirstein as Chief Executive Officer of the Company, without cause, effective immediately.
On February 3, 2025 (i) each of Timothy Ramdeen, Alastair Riddell and James Sapirstein resigned as directors of the Company
the Company’s Board of Directors appointed Manpreet Uppal, Alson Niu and Richard Joel Paolone as directors of the Company
the Company’s Board of Directors appointed Manpreet Uppal, Alson Niu and Richard Joel Paolone as directors of the Company
the Company’s Board of Directors appointed Manpreet Uppal, Alson Niu and Richard Joel Paolone as directors of the Company
On February 3, 2025 (i) each of Timothy Ramdeen, Alastair Riddell and James Sapirstein resigned as directors of the Company
On February 3, 2025 (i) each of Timothy Ramdeen, Alastair Riddell and James Sapirstein resigned as directors of the Company
On August 16, 2024, Chaitan Khosla resigned as a member of the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”), effective immediately.
appointed Timothy R. Ramdeen as a member of the Board.
Max materiality 0.95 · Median 0.62 · Most common event other_material